elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Pemetrexed
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Pemetrexed
RIS
0.004
(Research Intensity Score)
Papers
241
Top papers
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2023 · 681 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
2023 · 670 citations
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · 151 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2023 · 270 citations
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2025 · 77 citations
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2023 · 253 citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
2018 · 6659 citations
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2025 · 59 citations
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
2020 · 1179 citations
Newest papers
Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
2026 · 2 citations
Model‐Based Meta‐Analysis of Overall Survival in Vulnerable Platinum‐Ineligible NSCLC Populations
2026 · 2 citations
Editorial: Immunotherapeutic advances in brain tumours
2026
Occult lung adenocarcinoma diagnosed by EBUS-TBNA after pneumothorax resolution in an RA-ILD patient with respiratory failure
2026
Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives
2026
Case Report: squamous transformation after long-term osimertinib in EGFR-mutant lung adenocarcinoma with retained EGFR/TP53 alterations
2026
Pharmaceutical Verification of Chemotherapy-induced Adverse Events
2026
Cost-Effectiveness Analysis of Carboplatin-Paclitaxel, Cisplatin-Pemetrexed, and Carboplatin-Gemcitabine Chemotherapy Regimens in Patients with Non-Small Cell Lung Cancer at Persahabatan Central General Hospital
2026
Cost-effectiveness analysis of sacituzumab tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-mutated advanced NSCLC in China
2026
Browse all papers →
Pemetrexed's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Pemetrexed's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link